Cited by 635Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 197 of the 200 references it cites were found in a registry or an index, and 3 are not checked yet.

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Open access

Viola, Kirsten L., Klein, William L.·2015·Acta Neuropathologica

DOI 10.1007/s00401-015-1386-3PMC PMC4390393

Open this paper in CoChat — free account

Abstract

Protein aggregation is common to dozens of diseases including prionoses, diabetes, Parkinson's and Alzheimer's. Over the past 15 years, there has been a paradigm shift in understanding the structural basis for these proteinopathies. Precedent for this shift has come from investigation of soluble Aβ oligomers (AβOs), toxins now widely regarded as instigating neuron damage leading to Alzheimer's dementia. Toxic AβOs accumulate in AD brain and constitute long-lived alternatives to the disease-defining Aβ fibrils deposited in amyloid plaques. Key experiments using fibril-free AβO solutions demonstrated that while Aβ is essential for memory loss, the fibrillar Aβ in amyloid deposits is not the agent. The AD-like cellular pathologies induced by AβOs suggest their impact provides a unifying mechanism for AD pathogenesis, explaining why early stage disease is specific for memory and accounting for major facets of AD neuropathology. Alternative ideas for triggering mechanisms are being actively investigated. Some research favors insertion of AβOs into membrane, while other evidence supports ligand-like accumulation at particular synapses. Over a dozen candidate toxin receptors have been proposed. AβO binding triggers a redistribution of critical synaptic proteins and induces hyperactivity in metabotropic and ionotropic glutamate receptors. This leads to Ca(2+) overload and instigates major facets of AD neuropathology, including tau hyperphosphorylation, insulin resistance, oxidative stress, and synapse loss. Because different species of AβOs have been identified, a remaining question is which oligomer is the major pathogenic culprit. The possibility has been raised that more than one species plays a role. Despite some key unknowns, the clinical relevance of AβOs has been established, and new studies are beginning to point to co-morbidities such as diabetes and hypercholesterolemia as etiological factors. Because pathogenic AβOs appear early in the disease, they offer appealing targets for therapeutics and diagnostics. Promising therapeutic strategies include use of CNS insulin signaling enhancers to protect against the presence of toxins and elimination of the toxins through use of highly specific AβO antibodies. An AD-dependent accumulation of AβOs in CSF suggests their potential use as biomarkers and new AβO probes are opening the door to brain imaging. Overall, current evidence indicates that Aβ oligomers provide a substantive molecular basis for the cause, treatment and diagnosis of Alzheimer's disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00401-015-1386-3

Cites

197 of 200 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
Retracted
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citation
Journal of Biological Chemistry
Kurkinensp, M., CondongT, M. R., Blumberg, B., Barlow, D. P., Quiñones, S., Sausg, J., & Pihlajaniemisyy, T. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc · Cited by 3,427
Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
High-Level Neuronal Expression of Aβ1–42in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856

Show all 198 references

Research works printed but not linked: 1

Nigh AB, Vahedi S, Davis EG, Weintraub S, Bigio EH, Klein WL, Geula C (2014) Intracellular Amyloid-beta in cholinergic neurons. Brain J Neurol: In Press

Sorted by citations

Items 501–600 of 635

Oxysterol-binding protein ORP6 regulates lipid metabolism and brain Aβ production
Kasongo, A. A., Vijithakumar, V., Abd‐Elrahman, K. S., Prabhune, R., Gharibeh, L., Nadeau, R., Frayne, I. R., Spring, S., Robichaud, S., Asif, S., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100868 · Cited by 4
ROS-responsive ecdysterone nanodelivery system ameliorates Alzheimer's disease via synergistic modulation of oxidative stress and amyloid-β deposition
Xing, H., Sun, X., Xing, L., Li, Q., Puyang, M., Liu, L., & Chen, D. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.167717 · Cited by 3
Rapamycin treatment reduces CD11c+ microglia and increases amyloid plaque load in 5xFAD mice
Ouk, K., Fernández‐Klett, F., Schormann, E., Greiner, A., Santaella, A., Fernández‐Zapata, C., Böttcher, C., Krüger, E., & Priller, J. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115709 · Cited by 4
Proposed Therapeutic Strategy to Combat Alzheimer’s Disease by Targeting Beta and Gamma Secretases
Kumar, D., Anand, P., & Singh, S. K. (2025) · Current Alzheimer Research · doi:10.2174/0115672050380899250602042028 · Cited by 3
Neurochemical Aspects of Alzheimer’s Type of Dementia
Farooqui, A. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816347-4.00003-9 · Cited by 4
Studies on the cross‐interaction between hIAPP and Aβ25–35 and the aggregation process in binary mixture by electrospray ionization‐ion mobility‐mass spectrometry
Pang, B., Zhuang, X., Bian, X., Liu, S., Liu, Z., & Song, F. (2020) · Journal of Mass Spectrometry · doi:10.1002/jms.4643 · Cited by 3
Copper ions, prion protein and Aβ modulate Ca levels in central nervous system myelin in an NMDA receptor-dependent manner
Tsutsui, S., Morgan, M. L., Tedford, H. W., You, H., Zamponi, G. W., & Stys, P. K. (2022) · Molecular Brain · doi:10.1186/s13041-022-00955-2 · Cited by 3
Protein Oligomer Engineering: A New Frontier for Studying Protein Structure, Function, and Toxicity
Liu, C., & Luo, J. (2023) · Angewandte Chemie · doi:10.1002/ange.202216480 · Cited by 3
Long term administration of loquat leaves and their major component, ursolic acid, attenuated endogenous amyloid-β burden and memory impairment
Iwasa, K., Yagishita, S., Yagishita-Kyo, N., Yamagishi, A., Yamamoto, S., Yamashina, K., Haruta, C., Asai, M., Maruyama, K., Shimizu, K., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-44098-3 · Cited by 3
Effect of dietary patterns on mild cognitive impairment and dementia: a machine learning bibliometric and visualization analysis
Lou, Y., Chen, X., Zhao, L., Xuc, N., Zhang, L., Hu, W., & Qiu, Y. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1378959 · Cited by 3
Neuropathology of HIV-1 Disease
Soontornniyomkij, V. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7290-6_8 · Cited by 3
A Novel Optical Quantal Analysis of Miniature Events Reveals Enhanced Frequency Following Amyloid β Exposure
Taylor, H. B. C., Tong, R., Jeans, A. F., & Emptage, N. J. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.564081 · Cited by 3
Tau and beta-amyloid in Alzheimer’s Disease: Theories, treatments strategies, and future directions
Colautti, J., & Nagales, K. (2020) · The Meducator · doi:10.15173/m.v1i37.2502 · Cited by 3
Residue Interaction Network Analysis Predicts a Val24–Ile31 Interaction May be Involved in Preventing Amyloid‐Beta (1–42) Primary Nucleation
Griffin, J. W. D., & Bradshaw, P. C. (2021) · The Protein Journal · doi:10.1007/s10930-021-09965-w · Cited by 3
Understanding the pathophysiology of alzheimer's disease
Alharbi, S. S., Alharbi, S. S., Alanazi, A. F., & Alomran, R. W. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns10.15185 · Cited by 2
Efficient nose-to-brain delivery of nine residues peptide (JAL-TA9) exhibiting hydrolytic activity against amyloid-β
Hatakawa, Y., Tanaka, A., Furubayashi, T., Katsumi, H., Nakamura, R., Konishi, M., Akizawa, T., & Sakane, T. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114661 · Cited by 3
Converging Structural Biology and Nanotechnology to Decipher and Target Alzheimer’s Disease: From Atomic Insights to Clinical Translation
Patne, A. Y., Bagban, I., & Suryawanshi, M. V. (2025) · BioChem · doi:10.3390/biochem5040040 · Cited by 3
Antioxidants Trolox and Methazolamide Protect Microvascular Endothelial Cells from Oxidative Damage Induced by Sporadic and Familial Forms of Oligomeric Amyloid-β
Valle, M. L., Getaneh, B., William, C. M., Ghiso, J. A., & Rostagno, A. A. (2025) · Antioxidants · doi:10.3390/antiox14111375 · Cited by 2
Selective degradation of DAPK1 via a novel hydrophobic tagging attenuates tau pathology in Alzheimer’s disease
Li, R., Wu, X., Yao, J., Chen, J., Shui, X., Zheng, X., Tian, W., Wang, L., Zhou, Y., Zhang, T., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.12.037 · Cited by 2
A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease
Chen, T., Hutchison, R. M., Rubel, C. E., Murphy, J. M., Xie, J., O'Gorman, J. T., Dent, G. W., Molenberghs, G., Sormani, M. P., Hendrix, S. B., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100458 · Cited by 3
Amyloid Beta Oligomers as Early Triggers of Neuronal Cytoskeleton Dysfunction in Alzheimer’s Disease
Gasca-Martínez, Y., Ontiveros‐Torres, M. Á., López-Gallegos, I., & Jarero-Basulto, J. J. (2026) · Pathophysiology · doi:10.3390/pathophysiology33010014 · Cited by 2
A novel bifunctional peptide predicted to target neuropeptide Y4 and GLP-1 receptors alleviates cognitive deficits in 5 × FAD mice by modulating cGAS-STING-mediated neuroinflammation
Feng, Y., 张彩利, Wei, Y., Liu, E., Sun, H., Flatt, P., Gault, V. A., Irwin, N., Hölscher, C., Hao, L., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118074 · Cited by 2
TAU IMMUNOTHERAPY FOR ALZHEIMER’S (Review Article)
Chandrakumaran, A., Achuthaprasad, A., DANIEL, P., & JACOB, J. (2022) · EXPERIMENTAL & CLINICAL MEDICINE GEORGIA · doi:10.52340/jecm.2022.02.15 · Cited by 2
Inhibition of Amyloid-β Aggregation by p-Terphenyls from the Mushroom Polyozellus multiplex and Their Neuroprotective Effects
Kinoshita, K., Nakabayashi, S., Ishikura, A., Fujihara, K., Hirabayashi, S., Koike, S., Sasaki, H., Ogasawara, Y., & Koyama, K. (2022) · Heterocycles · doi:10.3987/com-22-14711 · Cited by 3
Advancing Alzheimer’s care: a novel therapy with lecanemab
Teli, A., & Dhande, P. P. (2023) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-023-00747-y · Cited by 2
The Effect of FTY720 on Sphingolipid Imbalance and Cognitive Decline in Aged EFAD Mice
Luo, Q., Crivelli, S. M., Zong, S., Giovagnoni, C., van Kruining, D., Mané-Damas, M., den Hoedt, S., Berkeš, D., de Vries, H. E., Mulder, M. T., et al. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230053 · Cited by 3
Balance between Association and Dissociation Rate Constants Determines Morphology and Property of Amyloid Fibrils
Nakagawa, T., Tsuri, D., Nishii, I., Kajimura, N., Matsuzaki, K., & Hoshino, M. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c07654 · Cited by 2
Proteomic Biomarkers in Alzheimer's disease
Cacabelos, R. (2016) · Diagnostic Pathology Open Access · doi:10.4172/2476-2024.1000103 · Cited by 2
SMPL Synaptic Membranes: Nanodisc-Mediated Synaptic Membrane Mimetics Expand the Toolkit for Drug Discovery and the Molecular Cell Biology of Synapses
Bu, R. L., Clark, J. R., DiChiara, T., Sligar, S. G., & Klein, W. L. (2018) · Neuromethods · doi:10.1007/978-1-4939-8739-9_13 · Cited by 2
Self-citation
Discovery of oxazolidinone-based heterocycles as subtype selective sigma-2 ligands
Blass, B. E., Bhandare, R. R., & Canney, D. J. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02848-4 · Cited by 2
Binding mechanism of full-length Aβ40 peptide to a mixed lipid bilayer
Wang, K., & Cai, W. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1367793 · Cited by 2
Neuroprotective poly(propylene imine) dendrimers with histidine- maltose shell reduce early amyloid aggregates and fibrils in Alzheimer’s disease transgenic micePreprint
Benseny‐Cases, N., Álvarez-Marimon, E., Aso, E., Carmona, M., Klementieva, O. L., Appelhans, D., Ferrer, I., & Cladera, J. (2021) · Research Square · doi:10.21203/rs.3.rs-379309/v1 · Cited by 2
Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer’s diseasePreprint
Salvadores, N., Moreno‐González, I., Gamez, N., Quiroz, G., Vegas, L., Escandón, M., Jiménez, S., Vitórica, J., Gutiérrez, A., Soto, C. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.27.457960 · Cited by 2
Curcumin Analogues as Novel Anti-Alzheimer's Candidates: Synthesis Development Strategy, In Vitro, Cell-Based and In Vivo Studies
Anas, Y., Susidarti, R. A., Yuniarti, N., & Martien, R. (2022) · INDONESIAN JOURNAL OF PHARMACY · doi:10.22146/ijp.4432 · Cited by 1
De Novo Transmembrane Aggregation of Aβ10–40 Peptides in an Anionic Lipid Bilayer
Vergilio, J., Lockhart, C., & Klimov, D. K. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01192 · Cited by 1
Self‐Destructive Nanoscavengers Capture and Clear Neurotoxic Soluble β‐Amyloid Aggregates
Zhao, Y., Li, Q., Huang, Q., & Liu, Y. (2023) · Macromolecular Rapid Communications · doi:10.1002/marc.202300378 · Cited by 1
Monoclonal antibody therapy in Alzheimer’s disease: an overview and vision
Bentley, J. H., Bishop, L. E., & Broussard, J. I. (2024) · Brain Network and Modulation · doi:10.4103/bnm.bnm_14_23 · Cited by 2
Inhibition of amyloid β aggregation and BACE1, and protective effect on SH-SY5Y cells, by p-terphenyl compounds from mushroom Thelephora aurantiotincta
Hirabayashi, S., Fujihara, K., Saito, T., Sasaki, H., Koike, S., Ogasawara, Y., Koyama, K., & Kinoshita, K. (2024) · Journal of Natural Medicines · doi:10.1007/s11418-024-01865-4 · Cited by 1
Oligomer sensitive in-situ detection and characterization of gold colloid aggregate formations observed within the hippocampus of the Alzheimer’s disease rat
Yokoyama, K., Mukkatt, J., Mathewson, N., Fazzolari, M. D., Hackert, V., Ali, M. M., Monichan, A. C., Wilson, A. J., Durisile, B. C., & Neuwirth, L. S. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138218 · Cited by 1
A Molecular Dynamics Investigation into Optimum Membrane‐Cholesterol Performance Influencing Alzheimer's‐Related Amyloid‐β Conformational Stability
Esawii, H. A., Arynbek, Y., Mohamed, N., Arzumanyan, G., & Mahran, H. A. (2025) · Advanced Theory and Simulations · doi:10.1002/adts.202500180 · Cited by 1
Ketone monoester alleviates cognitive impairment in a transgenic mouse model of Alzheimer’s disease through innate immunological IFITM3 pathway
Zhang, T., Ruan, J., Liu, Z., Yu, Y., Lü, Y., Zhang, X., Hou, C., Liu, X., Yuan, Y., & Han, X. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106094 · Cited by 2
Machine Learning-Enhanced Hyperspectral Raman Imaging for Label-Free Molecular Atlas of Alzheimer’s Brain
Wang, Z., Ranasinghe, J. C., Chan, D. C. Y., Gomm, A., Tanzi, R. E., Zhang, C. M., Zhang, N., & Huang, S. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c22623 · Cited by 1
Blood-based biomarkers and early diagnosis of Alzheimer’s disease
Cui, Z., Li, G., Wei, S., Cheng, Q., Yu, Q., Zong, S., Zhang, P., Chen, H., Yu, S., Wu, S., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00759 · Cited by 1
The metabolic roots of memory loss: interlinking the Diabetes-Alzheimer’s hypothesis
Gupta, T., Kumar, S., Singh, T. G., & Singh, R. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01824-w · Cited by 1
Baicalein alleviates Alzheimer’s disease pathology in AD models by activating the PI3K/AKT/GSK3β pathway to inhibit neuronal apoptosis
Cheng, W., Yang, S., Lu, Y., Wang, Y., & Tan, A.-H. (2026) · Scientific Reports · doi:10.1038/s41598-026-47003-w · Cited by 1
The mitochondria-synapse axis in Alzheimer’s disease: Lost coordination in early stages
Sharma, P., Kaur, N., Vasal, N., Solanki, K., & Sunkaria, A. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103168 · Cited by 1
Exploratory molecular dynamics study of pH-dependent β-strand propensity in aβ(14–23) oligomeric assemblies
Zein, H. F. (2026) · Chemical Physics · doi:10.1016/j.chemphys.2026.113284 · Cited by 1
Neuroinflammation in Alzheimer’s disease: glial crosstalk, pathological modulation, and therapeutic implications
Li, E., Zhang, P., & Feng, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1783786 · Cited by 1
Inhibition of miR-25-3p Alleviates Neuroinflammation in Alzheimer's Disease By Targeting ADAM10
Chen, P., Qiang, X., Zhao, Z., Wang, W. J., Zhen, H., & Liu, Y. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06042-0 · Cited by 1
Presynaptic accumulation of APP-CTFβ may contribute to synaptic dysfunction in Alzheimer’s disease
Kapadia, A., Schuhmann, F., Daşkın, E., Walter, J., Lindahl, I., Rahmani, N., Morrema, T. H. J., Rozemüller, A. J. M., Boon, B. D. C., Pezeshkian, W., et al. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00899-6 · Cited by 1
Contribution of Nucleic Acids in the Pathogenesis of Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00004-5 · Cited by 1
Intranasal applications in Alzheimer's treatment
Konaklı, M. İ. (2020) · Demiroglu Science University Florence Nightingale Journal of Medicine · doi:10.5606/fng.btd.2020.25038 · Cited by 1
Aumento da beta-amiloide em pacientes com privação do sono e sua associação com o Alzheimer: uma revisão de literatura
Araújo, A. C. O., Heinzen, R. S., & Moreira, C. E. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n1-618 · Cited by 1
Studies toward Identifying the Pharmacophore of L-755,807 for Amyloid-β Aggregation Inhibitory Activity
Kobayashi, K., Kogen, H., Tanaka, K., Honma, Y., & Suzuki, M. (2019) · Heterocycles · doi:10.3987/com-19-14193 · Cited by 1
Insulin resistance and Alzheimer’s disease
Farooqui, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819603-8.00006-7 · Cited by 1
Insulin resistance, diabetes, and metabolic syndrome
Farooqui, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819603-8.00002-x · Cited by 1
Aβ Fibrils Can Act as Aqueous Pores: a Molecular Dynamics StudyPreprint
Natesh, S., Sachleben, J. R., Sosnick, T. R., Freed, K. F., Meredith, S. C., & Haddadian, E. J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/418137 · Cited by 1
Retraction Note: In situ structural characterization of early amyloid aggregates in Alzheimer’s disease transgenic mice and Octodon degus
Benseny‐Cases, N., Álvarez-Marimon, E., Aso, E., Carmona, M., Klementieva, O. L., Appelhans, D., Ferrer, I., & Cladera, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-76208-w · Cited by 1
Retracted
The Effectiveness and Mechanisms of Acupuncture in Treating Alzheimer's DiseasePreprint
Li, N., Kang, X., Zhao, T., Song, J., Dong, H., Cheng, X., Wu, S., Zhou, L., Gong, Y., Chen, B., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3130204/v1 · Cited by 2
Investigating Alzheimer’s Disease Biomarkers by Applying Machine Learning ModelsPreprint
Khorsand, B., Salehi, S., Karimi, S., Karimipasand, S., Fariborzi, N., Houri, H., & Asri, N. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.19.643368 · Cited by 1
Residue-level structural information from isotope-edited FTIR spectroscopy reveals distinct molecular structures of different amyloid-β42 oligomersPreprint
Vosough, F., Carstensen, S. M., Baronio, C. M., & Barth, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.31.646305 · Cited by 1
Potential Animal Models of Alzheimer Disease and Their Importance in Investigating the Pathogenesis of Alzheimer Disease
Farooqui, A. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-15889-1_2
Featured Article A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects
Lues, I., Weber, F., Meyer, A., Uli, B., Hoffmann, T., Manhart, S., Heiser, U. F., Pokorny, R., Chiesa, J., & Glund, K. (2015)
The effect of the combination of erythromycin with new beta-lactam antibiotics against gram-negative aerobic respiratory pathogens.
Nakatomi, M., & Neu, H. C. (1986) · PubMed
Reversibility of Aβ oligomer neurotoxicity
Araki, W. (2017) · Oncotarget · doi:10.18632/oncotarget.19083
Secondary Prevention of Alzheimer’s Disease
Friel, H., & Frautschy, S. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812259-4.00004-7
Treatment Mechanisms in Mild to Moderate Alzheimer’s Disease
Friel, H., & Frautschy, S. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812259-4.00005-9
Neurochemical Aspects of β-Amyloid Cascade Hypothesis for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00001-x · Cited by 1
Perspective, Summary, and Directions for Future Research on Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00010-0
Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development
Huang, Y. H., Jia, H., & Bao, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00013-6
A Review on Animal Models of Alzheimer Disease
Singh, M. K., Wadhwa, P. K., & Sahu, S. K. (2018) · Journal of Emerging Technologies and Innovative Research
Construction of immune/Creutzfeldt–Jakob disease‐related gene coexpression network to predict biomarkers
Xiaoou, H., Zhou, J., & Liu, G. (2021) · European Journal of Neurology · doi:10.1111/ene.15063
Aluminum inhibits non-amyloid pathways via retinoic acid receptor
Li, H., Liu, Q., Li, L., Qin, X., Wang, S., Hu, J., Lu, X., Song, J., Jisheng, N., Zhang, Q., et al. (2021) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2021.126902
Neurochemical Aspects of Traumatic Brain Injury
Farooqui, A. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813596-9.00006-7 · Cited by 1
Alzheimer’s disease as a syndrome of overloaded amyloidic synaptic tagging in memory networksPreprint
Murphy, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/7gsaz
Tau and beta-amyloid in Alzheimer’s Disease: Theories, treatments strategies, and future directions
Colautti, J., & Nagales, K. (2021) · The Meducator · doi:10.35493/medu.37.12
Prion Protein Complex with mGluR5 Mediates Amyloid-ß Synaptic Loss in Alzheimer’s Disease
Roseman, G. P., Fu, L., & Strittmatter, S. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-20565-1_22
Long term administration of loquat (Eriobotrya japonica) leaves and their major component, ursolic acid, attenuated endogenous amyloid-β burden and memory impairmentPreprint
Iwasa, K., Yagishita, S., Yagishita-Kyo, N., Yamagishi, A., Yamamoto, S., Yamashina, K., Haruta, C., Asai, M., Maruyama, K., Shimizu, K., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2581351/v1
Intermediate antiparallel beta structure in amyloid plaques revealed by infrared spectroscopic imagingPreprint
Holcombe, B., Foes, A., Banerjee, S., Yeh, K. L., Wang, S. J., Bhargava, R., & Ghosh, A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.18.537414
Amyloid β oligomers dysregulate oligodendrocyte differentiation and myelination via PKC in the zebrafish spinal cordPreprint
Balantzategi, U., Gaminde‐Blasco, A., Bayón‐Cordero, L., Sánchez‐Gómez, M. V., Zugaza, J. L., Appel, B., & Alberdi, E. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.10.598246
Two major culprits: Amyloidogenic Aβ and non-amyloidogenic tau
Saido, T. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28979-8.00010-3
Unveiling the complexity of Alzheimer's disease: Introduction and its pathophysiology
Shabir, S., & Singh, M. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15540-6.00012-4
Therapeutic Role of Scutellarein in Neurological Disorders
Kumar, R., Bai, S., Shukla, R., & Naqvi, S. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128336901241125092132
Amyloid-β oligomers induced AD-like pathological changes in human cerebral organoids
Tang, Z., Luo, Y., Yan, J., & Yue, F. (2025) · Biophotonics and Immune Responses · doi:10.1117/12.3041186
Animal Models and Ethics in the Testing of Drugs for Alzheimer’s Disease
Roychowdhury, P., Justin, A., Gobinath, M., Karri, V. V. S. R., & Kuppusamy, G. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_17
Targeting amyloidogenic proteins through cyclic peptides – A medicinal chemistry perspective
Zargaham, M. K., Ibrahim, A., Ahmed, M., Babar, M. M., & Rajadas, J. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118165 · Cited by 1
Bibliometric analysis of pathological mechanisms in Alzheimer's disease: Applications based on mouse models
Li, J., Lin, Z., Niu, Y., Chang, W., Song, S., Yang, G., Liu, F., Dai, J., & Hao, C. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251367046
Five Small Molecule Compounds Targeting Aβ in Alzheimer’s Disease
Qu, S. (2024) · International Conference on Universal Village (UV) · doi:10.1109/uv63228.2024.11189166
Gaining insights into Alzheimer’s disease by predicting chromatin spatial organization
Villamán, C., Cartas‐Espinel, I., Sáez, M., & Martín, A. J. M. (2024) · Bioinformatics Advances · doi:10.1093/bioadv/vbaf268
Antibodies targeting amyloid-β and Tau oligomers in Alzheimer’s disease
Chinnathambi, S., Rangappa, N., & Chandrashekar, M. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.002
Additional file 1 of Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
Ettcheto, M., Sánchez‐López, E., Cano, A., Carrasco, M., Herrera, K., Manzine, P. R., Espinosa-Jiménez, T., Busquets, O., Verdaguer, E., Olloquequi, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15040849
Additional file 3 of Copper ions, prion protein and Aβ modulate Ca levels in central nervous system myelin in an NMDA receptor-dependent manner
Tsutsui, S., Morgan, M. L., Tedford, H. W., You, H., Zamponi, G. W., & Stys, P. K. (2022) · Figshare · doi:10.6084/m9.figshare.20381763
Additional file 1 of Copper ions, prion protein and Aβ modulate Ca levels in central nervous system myelin in an NMDA receptor-dependent manner
Tsutsui, S., Morgan, M. L., Tedford, H. W., You, H., Zamponi, G. W., & Stys, P. K. (2022) · Figshare · doi:10.6084/m9.figshare.20381757
Additional file 2 of Copper ions, prion protein and Aβ modulate Ca levels in central nervous system myelin in an NMDA receptor-dependent manner
Tsutsui, S., Morgan, M. L., Tedford, H. W., You, H., Zamponi, G. W., & Stys, P. K. (2022) · Figshare · doi:10.6084/m9.figshare.20381760
Additional file 1 of A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter
Mozzoni, K., Sheline, Y. I., Izzo, N. J., Yuede, C. M., Waybright, L., Yurko, R., Edwards, H. M., Gardiner, W. D., Blennow, K., Zetterberg, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22814988
Additional file 4 of Copper ions, prion protein and Aβ modulate Ca levels in central nervous system myelin in an NMDA receptor-dependent manner
Tsutsui, S., Morgan, M. L., Tedford, H. W., You, H., Zamponi, G. W., & Stys, P. K. (2022) · Figshare · doi:10.6084/m9.figshare.20381766
Envisioning the Neuroprotective Effect of Ocimum sanctum Linn (Tulsi) in Neurodegenerative Diseases: A Portrait of Molecular Crosstalk
Arora, D., Joshi, R., & Gupta, A. (2026) · Springer eBooks · doi:10.1007/978-981-95-4751-7_12
The Proteome of Human Amyloid Beta Oligomers
Kass, B., Poschmann, G., Demir, F., Huesgen, P. F., Stühler, K., Kutzsche, J., & Willbold, D. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00597 · Cited by 1
High-Fat Diet and a High Amyloid Load Interact to Induce PKC-α Dependent Synaptic Insulin Resistance
Wenger, A., Li, T., Nguyen, C., Celik, A., Cuboni, E., Dityatev, A. E., Karpova, A., Kreutz, M. R., & Ahrends, R. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101537
Optimal control of Alzheimer’s disease model via multi-target combination therapy
Dong, M., Guo, Z., Zhang, Y., Luo, J., & Zhang, J. (2026) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2026.112425

Authors: Viola, K. L., & Klein, W. L.
Affiliations: Northwestern University (US)
Corresponding author: Klein, William L.
ORCID: Viola, Kirsten L.
Klein, William L.
Venue: Acta Neuropathologica
Publisher: Springer Science and Business Media LLC
Published: 2015-01-22
Volume: 129
Issue: 2
Pages: 183-206
ISSN: 0001-6322 (ISSN-L)
1432-0533
DOI: 10.1007/s00401-015-1386-3
PMC: PMC4390393
OpenAlex: W2055775253
Cited by: 628
References: 198
Citations by year: 2026: 42 · 2025: 45 · 2024: 55 · 2023: 51 · 2022: 75 · 2021: 69 · 2020: 66 · 2019: 58 · 2018: 60 · 2017: 53 · 2016: 42 · 2015: 10
FWCI: 6.76
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Acta Neuropathologica (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Institute on Aging (AG045637, AG029460, R01AG022547, AG022547, R01AG029460, R21AG045637)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: amyloid-beta oligomers, Alzheimer's disease pathogenesis, protein aggregation, neurotoxicity, synaptic dysfunction, glutamate receptors, calcium overload, tau hyperphosphorylation, insulin resistance, oxidative stress, synaptic loss, cerebrospinal fluid biomarkers, diabetes comorbidity, hypercholesterolemia, Alzheimer's disease therapeutics
MeSH terms: Alzheimer Disease, Animals, Humans, Neurons, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks